T. Rowe Price Associates
EBS icon

T. Rowe Price Associates’s Emergent Biosolutions EBS Stock Holding History

T. Rowe Price Associates’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$352K Buy
42,387
+3,404
+9% +$35.3K ﹤0.01% 2609
2025
Q4 		$482K Sell
38,983
-1,458
-4% -$15.6K ﹤0.01% 2414
2025
Q3 		$357K Buy
40,441
+1,614
+4% +$12.6K ﹤0.01% 2516
2025
Q2 		$248K Buy
38,827
+27,027
+229% +$155K ﹤0.01% 2611
2025
Q1 		$58K Hold
11,800
– – ﹤0.01% 2907
2024
Q4 		$113K Hold
11,800
– – ﹤0.01% 2814
2024
Q3 		$99K Buy
+11,800
New +$107K ﹤0.01% 2821
2024
Q2 		– Sell
-23,943
Closed -$61K – 2950
2024
Q1 		$61K Buy
23,943
+4,409
+23% +$9.94K ﹤0.01% 2851
2023
Q4 		$47K Buy
19,534
+1,339
+7% +$3.15K ﹤0.01% 2814
2023
Q3 		$62K Sell
18,195
-9,495
-34% -$52.6K ﹤0.01% 2748
2023
Q2 		$204K Buy
27,690
+4,059
+17% +$37.6K ﹤0.01% 2524
2023
Q1 		$245K Buy
23,631
+914
+4% +$11K ﹤0.01% 2439
2022
Q4 		$268K Sell
22,717
-5,422
-19% -$83.9K ﹤0.01% 2410
2022
Q3 		$592K Sell
28,139
-104,788
-79% -$2.92M ﹤0.01% 2043
2022
Q2 		$4.13M Sell
132,927
-118,762
-47% -$4.05M ﹤0.01% 1449
2022
Q1 		$10.3M Sell
251,689
-20,384
-7% -$899K ﹤0.01% 1362
2021
Q4 		$11.8M Sell
272,073
-268,476
-50% -$12.1M ﹤0.01% 1385
2021
Q3 		$27.1M Sell
540,549
-13,487
-2% -$817K ﹤0.01% 1216
2021
Q2 		$34.9M Sell
554,036
-221,018
-29% -$14.2M ﹤0.01% 1157
2021
Q1 		$72M Sell
775,054
-97,313
-11% -$9.97M 0.01% 872
2020
Q4 		$78.2M Sell
872,367
-13,404
-2% -$1.23M 0.01% 812
2020
Q3 		$91.5M Buy
885,771
+11,369
+1% +$1.23M 0.01% 680
2020
Q2 		$69.1M Sell
874,402
-9,168
-1% -$683K 0.01% 742
2020
Q1 		$51.1M Sell
883,570
-5,769
-0.6% -$332K 0.01% 776
2019
Q4 		$48M Buy
889,339
+18,811
+2% +$1.02M 0.01% 922
2019
Q3 		$45.5M Buy
870,528
+57,295
+7% +$2.67M 0.01% 906
2019
Q2 		$39.3M Sell
813,233
-2,424
-0.3% -$116K 0.01% 965
2019
Q1 		$41.2M Buy
815,657
+50,403
+7% +$2.97M 0.01% 949
2018
Q4 		$45.4M Buy
765,254
+34,492
+5% +$2.22M 0.01% 865
2018
Q3 		$48.1M Buy
730,762
+118,273
+19% +$6.9M 0.01% 926
2018
Q2 		$30.9M Buy
612,489
+279,207
+84% +$14.5M ﹤0.01% 1059
2018
Q1 		$17.5M Buy
333,282
+319,092
+2,249% +$15.9M ﹤0.01% 1227
2017
Q4 		$659K Sell
14,190
-10
-0.1% -$421 ﹤0.01% 1979
2017
Q3 		$574K Hold
14,200
– – ﹤0.01% 2038
2017
Q2 		$482K Buy
14,200
+10
+0.1% +$309 ﹤0.01% 2078
2017
Q1 		$412K Buy
14,190
+10
+0.1% +$304 ﹤0.01% 2137
2016
Q4 		$466K Buy
14,180
+4,200
+42% +$126K ﹤0.01% 2077
2016
Q3 		$315K Buy
+9,980
New +$290K ﹤0.01% 2196
2013
Q4 		– Sell
-13,673
Closed -$260K – 2494
2013
Q3 		$260K Buy
+13,673
New +$244K ﹤0.01% 2166

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

T. Rowe Price Associates's EBS Position: Q1 2026 in Review

T. Rowe Price Associates increased its Emergent Biosolutions (EBS) stake by 8.7% in Q1 2026, buying an estimated $35.3K and bringing the position to 42,387 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #2609.

T. Rowe Price Associates first reported a position in EBS in Q3 2013 and has held it in 39 quarters since. The position peaked at $91.5M in Q3 2020. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • T. Rowe Price Associates held 42,387 shares of Emergent Biosolutions worth $352K as of Q1 2026.
  • T. Rowe Price Associates bought 3,404 Emergent Biosolutions shares in Q1 2026, an estimated $35.3K.
  • Emergent Biosolutions made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2609 holding.
  • T. Rowe Price Associates first reported a position in Emergent Biosolutions in Q3 2013 and has held it in 39 quarters since.
  • T. Rowe Price Associates's Emergent Biosolutions position peaked at $91.5M in Q3 2020.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.